Following last night’s American Society for Radiation Oncology Townhall, Bridge Oncology is continuing to push further upstream—to the source—with CMS, payers, and industry stakeholders as the current environment rapidly evolves. The takeaway from the discussion was clear: there is no near-term relief in sight for the disruption across reimbursement, payer behavior, and policy alignment. While ASTRO indicated they may release Active Motion Management (AMM) definitions by late summer, this remains a delayed response relative to the market need, particularly as Bridge Oncology had already developed and distributed AMM guidance to CMS, payers, and industry earlier this year (attached). The session itself reflected awareness but fragmentation, with approximately 110 attendees (likely closer to ~68 core participants excluding staff and non-physicians), underscoring a market that recognizes the issue but lacks coordinated direction or engagement.
Operationally, the environment continues to tighten. Denials—especially those tied to medical necessity and AMM interpretation—are accelerating, while the appeals process is proving unsustainable given bandwidth constraints. Many organizations are pausing projects amid financial uncertainty, while vendors are simultaneously increasing pressure through more aggressive sales strategies and embedded service offerings that raise concerns around alignment and conflicts of interest. We are also seeing early signs of structural contraction, with 14 radiation oncology centers now expected to close before the end of summer, and traditional PSA models rapidly becoming non-viable, forcing reassessment of coverage, alignment, and staffing structures.
In response, Bridge Oncology is not waiting for downstream clarity—we are advancing solutions now. Our 3-phase partnership model, spanning EPIC and data infrastructure alignment, operational integration, and total cost of care strategy across radiation oncology and full oncology services, is increasingly becoming a lifeline for systems navigating this disruption. Attached is updated hypofractionation compression data illustrating the impact between 77407 and 77412 utilization, which continues to be a primary driver of margin degradation beyond headline reimbursement changes. At the same time, we are deepening direct payer engagement using data-driven clinical and operational frameworks while maintaining independence from vendor-driven models that may introduce long-term misalignment.
This is not a temporary disruption—it is a structural shift. Organizations that rely on appeals, wait for policy clarity, or delay operational transformation will continue to face increasing pressure, while those that proactively align workflows, clinical utilization, and cost structures will be positioned to stabilize and move forward. Please reach out if you have questions or want to discuss how these dynamics are impacting your program—we are actively engaged and available to support.
zoom.us
